Cargando…

Abciximab: a reappraisal of its use in coronary care

Platelet reactivity plays a pivotal role in the pathogenesis of ischemic adverse events during and after acute coronary syndromes (ACS), and percutaneous coronary intervention (PCI). Glycoprotein (GP) IIb/IIIa inhibitors are the strongest antiplatelet agents currently available on the market and thr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valgimigli, Marco, Campo, Gianluca, Tebaldi, Matteo, Carletti, Roberto, Arcozzi, Chiara, Ferrari, Roberto, Percoco, Gianfranco
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727773/ https://www.ncbi.nlm.nih.gov/pubmed/19707425

Ejemplares similares

Abciximab: Abciximab-induced alveolar haemorrhage: case report
Publicado: (2021)

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
por: Vergara-Jimenez, Jennifer, et al.
Publicado: (2010)

Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban
por: Campo, Gianluca, et al.
Publicado: (2010)

Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?
por: Gargiulo, Giuseppe, et al.
Publicado: (2017)

Alveolar Hemorrhage during Abciximab Infusion
por: Koza, Yavuzer, et al.
Publicado: (2021)

Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab
por: Moon, Su-Jin, et al.
Publicado: (2008)

Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine Coronary Restenosis Model
por: Hong, Young Joon, et al.
Publicado: (2007)

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio
por: Voisard, Rainer, et al.
Publicado: (2006)

Intracoronary versus Intravenous Administration of Abciximab in Patients with Acute Coronary Syndrome: A Meta-Analysis
por: Wang, Jie-Ning, et al.
Publicado: (2013)

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report
por: Kul, Selim, et al.
Publicado: (2017)

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome
por: Shakoor, Muhammad Tariq, et al.
Publicado: (2014)

Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact
por: Rgeeb, Ahmed N., et al.
Publicado: (2020)

A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab.
por: Jeong, M. H., et al.
Publicado: (2001)

Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis
por: Wu, Yihua, et al.
Publicado: (2011)

Effect of a Dual Drug-Coated Stent With Abciximab and Alpha-Lipoic Acid in a Porcine Coronary Restenosis Model
por: Lim, Kyung Seob, et al.
Publicado: (2011)

Coronary Microvascular Dysfunction: PET, CMR and CT Assessment
por: Tonet, Elisabetta, et al.
Publicado: (2021)

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
por: Park, Soonyoung, et al.
Publicado: (2013)

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)

Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept Study
por: Tebaldi, Matteo, et al.
Publicado: (2020)

Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence
por: Ferrari, Marco, et al.
Publicado: (2021)

Intracoronary physiology-guided percutaneous coronary intervention in patients with diabetes
por: Scarsini, Roberto, et al.
Publicado: (2023)

Coronary artery anomalies presenting with ST-segment elevation myocardial infarction
por: Marchesini, Jlenia, et al.
Publicado: (2011)

Diagnostic reasoning in internal medicine: a practical reappraisal
por: Corazza, Gino Roberto, et al.
Publicado: (2020)

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
por: Namazi, Mohammad Hasan, et al.
Publicado: (2013)

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion
por: Bertuglia, Silva, et al.
Publicado: (2002)

Effect of Abciximab on the Levels of Circulating Microparticles in Patients with Acute Myocardial Infarction Treated by Primary Angioplasty
por: Cha, Jung-Joon, et al.
Publicado: (2013)

Efficacy of Combination Treatment with Intracoronary Abciximab and Aspiration Thrombectomy on Myocardial Perfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Stenting
por: Ahn, Sung Gyun, et al.
Publicado: (2014)

Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry)
por: Dziewierz, Artur, et al.
Publicado: (2012)

Spontaneous Bleeding from Internal Pudendal Artery associated with Abciximab after Primary Percutaneous Coronary Intervention: Successful Treatment with Percutaneous Gel-Foam Embolization
por: Lee, Seung-Eun, et al.
Publicado: (2016)

Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study
por: Kretzschmar, Daniel, et al.
Publicado: (2012)

Relationship between the duration of ischemia and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012)

Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI
por: Tödt, Tim, et al.
Publicado: (2012)

High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI – The Tamip Study
por: Balghith, Mohammed A.
Publicado: (2012)

The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro(®)) Coated Stent in Patients with Coronary Artery Disease
por: Kim, Weon, et al.
Publicado: (2004)

Angina and left ventricular dysfunction: can we ‘reduce’ it?
por: Biscaglia, Simone, et al.
Publicado: (2019)

Efficacy of Femoral Vascular Closure Devices in Patients Treated with Anticoagulant, Abciximab or Thrombolytics during Percutaneous Endovascular Procedures
por: Kim, Ha Young, et al.
Publicado: (2006)

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
por: Gu, Youlan L, et al.
Publicado: (2009)

Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials
por: Bai, Nan, et al.
Publicado: (2022)

HDL cholesterol: reappraisal of its clinical relevance
por: März, Winfried, et al.
Publicado: (2017)

In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome
por: Campioni, Diana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mfq9lc5adv6l0vhguf3trdoqek